Because ERRα belongs to a class of druggable NRs, our in vitro and in vivo studies suggest that the ERRα antagonist XCT790 might be considered as a potential drug to treat colon cancer patients with defective p53 status. This evidence concerns the gene TP53 and malignant colon neoplasm.